OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells

Wang, Dailian; Chen, Zhicong; Fan, Lin; Wang, Ziqiang; Gao, Qiufeng; Xie, Haibiao; Xiao, Huizhong; Zhou, Yifan; Zhang, Fuyou; Ma, Yingfei; Mei, Hongbin; Cai, Zhiming; Liu, Yuchen; Huang, Weiren

doi:10.7150/jca.27381

Cited by 22 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OIP5 is also known as Miss18β, that plays a critical role in centromere formation during the G1 phase (165,166). In accordance with this knowledge, OIP5 is an independent risk factor for BCR (HR, 1.94; 95% CI, 1.20-3.12; P=0.00638) after adjusting for age at diagnosis, GS, surgical margin and tumor stage (156); OIP5 promotes bladder cancer metastasis and chemoresistance (167), glioblastoma metastasis (168), it displays a biomarker potential in clear cell renal cell carcinoma (169), and it is upregulated in colorectal and breast cancer (170,171).…”

Section: Gene Expression-based Biomarkerssupporting

confidence: 59%

Assessment of biochemical recurrence of prostate cancer (Review)

Lin

Kapoor

et al. 2019

Int J Oncol

View full text Add to dashboard Cite

The assessment of the risk of biochemical recurrence (BCR) is critical in the management of males with prostate cancer (PC). Over the past decades, a comprehensive effort has been focusing on improving risk stratification; a variety of models have been constructed using PC-associated pathological features and molecular alterations occurring at the genome, protein and RNA level. Alterations in RNA expression (lncRNA, miRNA and mRNA) constitute the largest proportion of the biomarkers of BCR. In this article, we systemically review RNA-based BCR biomarkers reported in PubMed according to the PRISMA guidelines. Individual miRNAs, mRNAs, lncRNAs and multigene panels, including the commercially available signatures, Oncotype DX and Prolaris, will be discussed; details related to cohort size, hazard ratio and 95% confidence intervals will be provided. Mechanistically, these individual biomarkers affect multiple pathways critical to tumorigenesis and progression, including epithelial-mesenchymal transition (EMT), phosphatase and tensin homolog (PTEN), Wnt, growth factor receptor, cell proliferation, immune checkpoints and others. This variety in the mechanisms involved not only validates their associations with BCR, but also highlights the need for the coverage of multiple pathways in order to effectively stratify the risk of BCR. Updates of novel biomarkers and their mechanistic insights are considered, which suggests new avenues to pursue in the prediction of BCR. Additionally, the management of patients with BCR and the potential utility of the stratification of the risk of BCR in salvage treatment decision making for these patients are briefly covered. Limitations will also be discussed. Contents 1. Introduction 2. Stratification of BCR risk: An update 3. Searching methods for RNA-based BCR biomarkers 4. Gene expression-based biomarkers 5. Management of patients with biochemical recurrence 6. Perspectives

show abstract

Section: Gene Expression-based Biomarkerssupporting

confidence: 59%

Assessment of biochemical recurrence of prostate cancer (Review)

Lin

Kapoor

et al. 2019

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…OIP5 was found to be highly expressed in many types of cancer. Studies have confirmed its role in the progression of hepatocellular, bladder, and gastric cancers 35–37 . Interestingly, OIP5 was also recognized as a downstream gene of E2F1 in the tumorigenesis and metastasis of glioblastoma, 38 which is consistent with the GSEA enrichment to E2F target in our study (Figure S3A,B).…”

Section: Discussionsupporting

confidence: 89%

Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism‐related genes act as prognostic signatures for prostate cancer

et al. 2020

View full text Add to dashboard Cite

BackgroundThe Warburg effect seen in most solid tumors occurs only in the late stages of prostate cancer (PCa). Currently, the management of patients with low‐risk localized PCa and patients after radical therapy remains a challenge. Our objective here was to evaluate glycometabolism‐related genes as prognostic signatures for PCa.MethodsThe International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) databases and glycometabolism‐related gene sets were obtained online. Glycometabolic prognostic signatures were identified and validated in a TCGA cohort and tested in an ICGC cohort. We used the gene set enrichment analysis to reveal biological processes associated with the glycometabolism‐related signatures. Novel glycometabolism‐related genes were selected for verifying their oncogenic phenotypes in vitro.ResultsTwo glycometabolic prognostic signatures were applied respectively to construct risk score formulas for PCa. Survival and receiver operating characteristic curve analyses were performed to detect the value of these prognostic signatures. We performed univariate and multivariate Cox regression analyses in the TCGA cohort, demonstrating the independence of the prognostic signatures. Three glycometabolism‐related genes were found to be novel PCa‐associated genes. These were shown to affect proliferation, cell cycle progression, and glycolysis of DU145 and PC3 cells in different degrees.ConclusionThe present research represents the first glycometabolic and high‐throughput investigation on PCa, revealing potential biomarkers and treatment targets. We confirm the vital role of glycometabolism in PCa and provide essential resources for future exploration of metabolism in PCa.

show abstract

“…Chemotherapy is an important treatment for BC, and cisplatin is considered to be the first-line chemotherapy for advanced BC [ 83 ]. However, due to drug toxicity and heterogeneity among patients, 40–60% of patients with bladder cancer do not respond to cisplatin-based systemic chemotherapy [ 84 , 85 ].…”

Section: Discussionmentioning

confidence: 99%

An HDAC9-associated immune-related signature predicts bladder cancer prognosis

Sun

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background The close relationship between histone deacetylase 9 (HDAC9) and immunity has attracted attention. We constructed an immune signature for HDAC9, a vital epigenetic modification, to predict the survival status and treatment benefits in bladder cancer (BC). Methods An exhaustive analysis of HDAC9 and immunology via the tumor and immune system interaction database (TISIDB) was performed, and an immune prognostic risk signature was developed based on genes enriched in the top five immune-related pathways under high HDAC9 status. Comprehensive analysis of survival curves and Cox regression were used to estimate the effectiveness of the risk signature. The relationship between immunological characteristics and the risk score was evaluated, and the mechanisms were also explored. Results In the TISIDB, HDAC9 was closely related to various immunological characteristics. The risk signature was obtained based on genes related to prognosis enriched in the top five immune-related pathways under high HDAC9 status. The survival rate of the high-risk BC patients was poor. The risk score was closely related to multiple immunological characteristics, drug sensitivity, immunotherapy benefits and biofunctions. Conclusion An immune-related prognostic signature established for HDAC9 expression status could independently predict the prognosis of BC patients. The use of this signature could help clinicians make personalized treatment decisions.

show abstract

OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells

Cited by 22 publications

References 50 publications

Assessment of biochemical recurrence of prostate cancer (Review)

Assessment of biochemical recurrence of prostate cancer (Review)

Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism‐related genes act as prognostic signatures for prostate cancer

An HDAC9-associated immune-related signature predicts bladder cancer prognosis

Contact Info

Product

Resources

About